serum
sampl
healthi
volunt
match
vaccin
month
collect
store
singl
center
doseescal
clinic
trial
clinicaltrialsgov
identifi
inactiv
vaccin
conduct
nation
institut
allergi
infecti
diseas
nation
institut
health
vaccin
manufactur
sanofi
pasteur
use
trial
monoval
inactiv
subvirion
vaccin
rga
x
studi
conduct
accord
institut
review
protocol
enzymelink
immunosorb
assay
elisa
perform
test
crossreact
serum
sampl
multipl
influenza
subtyp
recombin
ha
protein
includ
anew
anetherland
express
insect
cell
trimer
ha
ectodomain
ha
protein
coat
onto
maxisorb
elisa
plate
nunc
phosphatebuff
salin
pb
overnight
plate
wash
pb
time
remov
uncoat
protein
serial
dilut
serum
sampl
appli
hacoat
plate
follow
horseradish
peroxidas
hrp
antihuman
igg
igm
pierc
biotechnolog
detect
igg
igm
variou
ha
subtyp
serum
sampl
optic
densiti
nm
measur
incub
peroxidas
tetramethylbenzidin
substrat
system
competit
elisa
assay
conduct
determin
level
ab
serum
sampl
ab
human
biotinyl
sulfonhsssbiotin
pierc
biotechnolog
accord
manufactur
instruct
biotinyl
ngml
mix
vol
ratio
serum
sampl
variou
dilut
ad
elisa
plate
coat
trimer
competit
serum
sampl
bind
determin
measur
remain
bind
use
hrpstreptavidin
bd
bioscienc
isol
ab
ab
intraven
immunoglobulin
ivig
mgml
gamunex
ivig
talecri
biotherapeut
first
immobil
protein
magnet
bead
dynabead
epoxi
invitrogen
accord
manufactur
manual
use
stepwis
elut
acid
elut
separ
ab
ab
present
ivig
specif
incub
ml
ivig
mgml
overnight
wash
extens
bsapb
follow
elut
total
overnight
remain
ab
isol
acid
elut
ph
buffer
next
eluent
acid
eluent
incub
bead
bead
invitrogen
h
time
time
respect
elisa
perform
verifi
sampl
complet
remov
bead
absorpt
purifi
ab
ab
well
unpurifi
ivig
quantifi
elisa
use
known
concentr
monoclon
ab
mab
standard
aforement
purif
procedur
scale
proport
obtain
enough
ab
ab
test
crossreact
differ
influenza
subtyp
elisa
pseudotyp
viru
neutral
assay
describ
elsewher
statist
analys
perform
use
pair
test
comparison
prevaccin
postvaccin
abbind
level
ab
inhibit
activ
neutral
activ
compar
use
microneutr
assay
mn
titer
proport
increas
ab
level
compar
mcnemar
test
pair
binari
outcom
p
valu
p
valu
consid
statist
signific
correl
igg
ab
mn
titer
postvaccin
serum
sampl
n
analyz
spearman
rank
correl
coeffici
analysi
vaccin
group
prevaccin
igm
recombin
protein
detect
major
studi
subject
igm
bind
level
increas
significantli
vaccin
p
howev
subject
demonstr
increas
shown
increas
optic
densiti
nm
elisa
figur
studi
subject
preimmun
igg
ab
bound
figur
expect
bind
p
figur
neutral
activ
mn
titer
vaccin
strain
p
figur
significantli
increas
vaccin
igg
recombin
protein
figur
protein
figur
also
detect
preimmun
serum
sampl
contrast
postvaccin
igg
bind
increas
significantli
p
howev
increas
reach
statist
signific
p
proport
specimen
increas
bind
significantli
lower
bind
vs
p
investig
presenc
heterosubtyp
bnab
serum
probe
serum
sampl
presenc
igg
ab
determin
inhibit
bind
biotinyl
competit
elisa
assay
found
ab
could
compet
bind
also
present
prevaccin
serum
specimen
sampl
demonstr
inhibit
bind
dilut
figur
furthermor
igg
titer
increas
significantli
vaccin
p
major
vaccine
increas
addit
weak
signific
correl
igg
mn
titer
postimmun
serum
sampl
determin
spearman
rank
correl
analysi
coeffici
howev
stem
pocketdirect
bnab
reach
high
enough
level
render
strongli
signific
correl
determin
whether
bnab
uniqu
subject
popul
test
present
broadli
quantifi
ab
commerci
ivig
determin
breadth
heterosubtyp
bind
neutral
activ
ivig
contain
pool
igg
thousand
donor
repres
preimmun
igg
ab
composit
gener
popul
although
formal
rule
ivig
truli
naiv
best
repres
sampl
avail
studi
magnet
bead
use
affinitypurifi
ab
ivig
ab
isol
competit
elut
total
bound
ab
remain
ab
releas
acid
elut
quantit
elisa
found
mg
ivig
ab
bound
plate
total
could
purifi
use
affin
purif
acid
elut
final
yield
acidelut
competit
elut
yield
ab
per
mg
ivig
total
ig
level
similar
higher
effici
recoveri
compar
acid
elut
ab
test
heterosubtyp
ha
bind
neutral
activ
group
virus
acidelut
ab
specif
show
crossbind
activ
weakli
figur
neutral
asouth
pseudotyp
viru
infect
figur
elut
ab
show
group
specif
expect
bound
group
group
ii
figur
also
neutral
pseudovirus
figur
studi
show
prevaccin
serum
sampl
baselin
heterosubtyp
ha
ab
bind
activ
group
ha
subtyp
includ
subject
like
unexpos
us
geograph
locat
igm
igg
ab
increas
significantli
vaccin
wherea
happen
igg
ab
igg
ab
also
detect
preimmun
serum
sampl
increas
significantli
vaccine
low
level
serum
antiha
ab
bind
neutral
virus
report
age
influenza
exposur
depend
investig
report
enhanc
level
hadirect
neutral
ab
healthi
donor
boost
unrel
human
influenza
season
vaccin
serum
ab
may
direct
group
stem
pocket
ha
inde
corti
et
al
show
major
season
vaccine
preexist
neutral
ab
titer
pseudotyp
virus
markedli
increas
season
vaccin
ha
stempocket
direct
ab
present
rel
low
level
compar
ab
bind
globular
head
ha
also
observ
increas
group
reactiv
group
vaccin
figur
precis
locat
crossbind
epitop
current
known
observ
support
possibl
presenc
heterosubtyp
ab
broader
type
bind
group
virus
also
seen
children
primari
influenza
infect
mucos
vaccin
experiment
anim
one
studi
crossneutr
murin
mab
hemagglutin
inhibit
activ
group
group
recov
intranas
vaccin
mous
contrast
ab
mab
direct
globular
head
escap
mutant
readili
obtain
anim
vaccin
studi
shown
antibodi
fusion
peptid
linear
peptid
broad
reactiv
group
neutral
activ
respect
whether
differ
quantit
amount
group
bnab
andor
group
bnab
elicit
vaccin
natur
infect
remain
import
unansw
question
studi
quantifi
baselin
level
antiinfluenza
heterosubtyp
ab
human
serum
use
ivig
repres
preimmun
igg
ab
composit
gener
popul
includ
individu
like
expos
season
influenza
viru
infect
andor
vaccin
investig
shown
low
level
heterotyp
antiha
ab
bind
neutral
virus
present
ivig
divers
geograph
locat
investig
show
heterosubtyp
ab
crossreact
howev
effort
purifi
character
ab
beyond
neutral
titer
report
data
show
popul
heterosubtyp
ab
differ
ha
bind
abil
ivig
one
bind
group
group
virus
specif
direct
group
stem
pocket
approxim
ivig
certainli
deriv
donor
purifi
acid
elut
heterosubtyp
bind
activ
group
group
fraction
ivig
ab
also
demonstr
neutral
activ
pseudotyp
virus
stem
pocketdirect
ab
also
detect
ivig
recov
level
bind
ab
expect
ab
display
similar
bind
neutral
profil
among
test
virus
group
specif
mab
direct
stem
pocket
ha
ab
fraction
broader
rang
subtyp
test
due
limit
amount
ab
could
purifi
ivig
mg
ivig
respect
largerscal
purif
protein
materi
requir
character
heterosubtyp
bnab
detail
although
quantit
show
bnab
bind
group
present
low
level
well
stem
pocketdirect
bnab
exist
even
lower
level
question
whether
serum
ivig
protect
level
either
type
heterosubtyp
bnab
answer
studi
howev
quantit
data
support
notion
level
bnab
borderlin
titer
would
tradit
consid
protect
exampl
mg
ivig
assum
mgml
igg
normal
human
serum
concentr
ab
could
present
likewis
fraction
acid
elut
bnab
activ
group
could
also
rang
furthermor
observ
variabl
level
studi
patient
figur
remain
possibl
host
factor
includ
vh
polymorph
may
impact
baselin
induc
bnab
level
addit
origin
popul
heterosubtyp
antiha
ab
unknown
possibl
may
compon
natur
polyreact
ab
exclud
howev
like
vaccin
studi
subject
ivig
donor
prior
exposur
group
group
influenza
virus
either
season
vaccin
andor
natur
infect
may
given
rise
heterosubtyp
bind
ab
respect
summari
find
show
human
immun
system
capabl
make
conserv
pocket
ha
stem
group
virus
also
anoth
unknown
epitop
share
group
influenza
virus
observ
provid
basi
investig
aim
obtain
better
understand
bnab
origin
host
genet
factor
restrict
enabl
induct
addit
studi
bring
us
closer
develop
univers
influenza
vaccin
provid
durabl
protect
beyond
season
vaccin
mitig
abil
virus
undergo
neutral
escap
inde
recent
report
vaccin
induc
protect
level
group
stempocket
direct
bnab
experiment
evid
may
possibl
man
